Cases involving long-term users of Vioxx will, as Meredith Wadman reports, determine the true cost to Merck and the drug industry of the painkiller's withdrawal.
This is a preview of subscription content, log in via an institution to check access.
Related links
Related links
Related links in Nature Research
Journal grows suspicious of Vioxx data
Painkiller verdict shows mistrust of Merck
Related external links
Rights and permissions
About this article
Cite this article
Make or break time in Vioxx drama. Nature 440, 277 (2006). https://doi.org/10.1038/440277a
Published:
Issue Date:
DOI: https://doi.org/10.1038/440277a
- Springer Nature Limited
This article is cited by
-
News in brief
Nature (2006)
-
In brief
Nature (2006)
-
Editorial: Klinische Arzneimitteltherapie
Wiener Medizinische Wochenschrift (2006)